Through in vivo and in vitro experiments, we demonstrated that PEBP1 mRNA efficiently expresses and exerts a protective effect in nanovesicles, providing a potential molecular target for AAA treatment. The gene discussed is PEBP1; the disease is triple-A syndrome.